3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
7
Thoracic
2
Head & Neck
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Squamous Cell Carcinoma of Head and Neck
8
Esthesioneuroblastoma, Olfactory
8
Breast Neoplasms
8
Head and Neck Neoplasms
7
Salivary Gland Neoplasms
6
Lung Neoplasms
6
Urinary Bladder Neoplasms
5
Prostatic Neoplasms
5
Esophageal Neoplasms
5
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Ovarian Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Sarcoma
3
Osteosarcoma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Breast Neoplasms, Male
3
Sarcoma, Kaposi
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Nasopharyngeal Neoplasms
2
Melanoma
2
Medulloblastoma
2
Glioma
2
Colonic Neoplasms
2
Chondrosarcoma
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Interventions
trametinib
1
pembrolizumab
1
lenvatinib
1
dabrafenib
1
Nivolumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Docetaxel
×
CNS
×
Clear all
NCT05094336
2026-05-28
MTAPESTRY 101
Amgen
Phase 1/2
Active not recruiting
329 enrolled